OverviewSuggest Edit

Sutro Biopharma designs and develops a patient-centric collaboration tool. The Company is applying its technology to the development of next-generation, non-native protein structures such as antibody fragments, single-chain antibodies, and other proteins with novel scaffolds. 

TypePublic
Founded2003
HQSouth San Francisco, CA, US
Websitesutrobio.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Dec 2019)168
Job Openings25
Revenue (FY, 2020)$42.7 M
Share Price (Jan 2022)$10.4
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Sutro Biopharma

John G. Freund

John G. Freund

Director
Edward Albini

Edward Albini

Chief Financial Officer
Shabbir Anik

Shabbir Anik

Chief Technical Operations Officer
Trevor Hallam

Trevor Hallam

Chief Scientific Officer
William J. Newell

William J. Newell

Chief Executive Officer & Director
Linda Fitzpatrick

Linda Fitzpatrick

Chief People and Communications Officer
Show more

Sutro Biopharma Office Locations

Sutro Biopharma has offices in South San Francisco and San Carlos
South San Francisco, CA, US (HQ)
310 Utah Ave
San Carlos, CA, US
1000 Commercial St
South San Francisco, CA, US
111 Oyster Point Blvd
South San Francisco, CA, US
240 E Grand Ave
Show all (4)

Sutro Biopharma Financials and Metrics

Sutro Biopharma Revenue

Sutro Biopharma's revenue was reported to be $42.72 m in FY, 2020
USD

Revenue (FY, 2020)

42.7m

Net income (FY, 2020)

(32.1m)

EBIT (FY, 2020)

(71.1m)

Market capitalization (25-Jan-2022)

481.7m

Closing stock price (25-Jan-2022)

10.4

Cash (31-Dec-2020)

206.2m

EV

300.1m
Sutro Biopharma's current market capitalization is $481.7 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

59.7m51.7m38.4m42.7m42.7m

Revenue growth, %

(13%)

General and administrative expense

14.8m16.4m21.4m32.6m36.8m

R&D expense

43.6m54.6m54.3m65.6m77.0m
Quarterly
USDQ2, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

30.2m11.5m7.8m8.6m10.5m12.3m7.2m

General and administrative expense

7.4m8.5m5.4m7.7m8.1m8.1m8.7m

R&D expense

25.8m26.8m12.6m15.2m16.1m16.9m17.6m

Operating expense total

33.2m35.3m18.0m22.9m24.2m25.0m26.3m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

11.6m22.0m125.3m5.0m206.2m

Accounts Receivable

577.0k1.6m2.5m6.3m5.6m

Prepaid Expenses

1.6m2.0m3.0m4.4m4.5m

Current Assets

49.7m25.6m209.9m128.6m378.2m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

25.4m41.4m26.6m19.4m12.0m43.6m

Accounts Receivable

3.2m2.4m3.3m6.5m7.5m9.1m

Prepaid Expenses

1.6m2.6m3.0m

Current Assets

30.2m127.4m176.5m162.2m135.6m127.5m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

1.7m(19.7m)(35.3m)(55.7m)(32.1m)

Depreciation and Amortization

5.7m5.0m4.5m4.8m4.3m

Accounts Payable

874.0k(473.0k)209.0k2.3m(947.0k)

Cash From Operating Activities

(13.2m)(37.1m)12.7m(65.0m)(67.8m)
Quarterly
USDQ2, 2017Q2, 2018Q1, 2019Q1, 2020

Net Income

(2.9m)(23.6m)(14.2m)(19.6m)

Depreciation and Amortization

1.1m1.1m

Accounts Payable

(756.0k)(650.0k)476.0k

Cash From Operating Activities

(30.2m)(29.0m)(20.1m)(18.7m)
USDFY, 2016

Financial Leverage

6 x
Show all financial metrics

Sutro Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Sutro Biopharma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Sutro Biopharma Online and Social Media Presence

Embed Graph

Sutro Biopharma News and Updates

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sutro Biopharma, Inc. - STRO

NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STRO).   Such investors are advised to contact Robert S. Willoughby at  newaction@pomlaw.com or 888-476-6529, ext. 7980.

Sutro Biopharma to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 6, 2022 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro" or the "Company") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...

Sutro Biopharma Announces Company KOL Virtual Event to Provide Interim Dose Expansion Data for Antibody-Drug Conjugate Program STRO-002 for Treatment of Advanced Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro"), (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...

Sutro Biopharma and Tasly Biopharmaceuticals Enter into Exclusive License Agreement for STRO-002 in Greater China

SOUTH SAN FRANCISCO, Calif. and SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. ("Sutro") (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021

SOUTH SAN FRANCISCO, Calif, Dec. 13, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Show more

Sutro Biopharma Frequently Asked Questions

  • When was Sutro Biopharma founded?

    Sutro Biopharma was founded in 2003.

  • Who are Sutro Biopharma key executives?

    Sutro Biopharma's key executives are John G. Freund, Edward Albini and Shabbir Anik.

  • How many employees does Sutro Biopharma have?

    Sutro Biopharma has 168 employees.

  • What is Sutro Biopharma revenue?

    Latest Sutro Biopharma annual revenue is $42.7 m.

  • What is Sutro Biopharma revenue per employee?

    Latest Sutro Biopharma revenue per employee is $254.3 k.

  • Who are Sutro Biopharma competitors?

    Competitors of Sutro Biopharma include Menlo Therapeutics, PRO Care Physical Therapy and Midwest Medical.

  • Where is Sutro Biopharma headquarters?

    Sutro Biopharma headquarters is located at 310 Utah Ave, South San Francisco.

  • Where are Sutro Biopharma offices?

    Sutro Biopharma has offices in South San Francisco and San Carlos.

  • How many offices does Sutro Biopharma have?

    Sutro Biopharma has 4 offices.